

05-26-04

1624 igu

EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number

EL 984 914 588 US

Date of Deposit

May 25, 2004

Type of Documents

Supplemental Information Disclosure

Statement;

Form 1449 (1 page);

Cited References / two (2); and

Return Postcard

Serial No.

09/864,905

Filing Date

May 24, 2001

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and are addressed to the Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450.

(signature)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re ap	plicati	on of: Miller, et al.) .	Examiner: Hong Liu
Serial No:		09/864,905		Art Unit: 1624
Filed:		May 24, 2001))	Docket No: T103 1421.1
For:	Pharmaceutical Compositions and Methods for Use)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants hereby voluntarily disclose the additional references listed on the attached Form PTO-1449 to the Commissioner for Patents. Copies of the two (2) references listed on Applicants' supplemental form PTO-1449 are enclosed herewith. Each item of information submitted with this Supplemental Information Disclosure Statement is being submitted before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. Accordingly, no fees are believed due. However, should any fees be due in connection with this submission, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. <u>09-0528</u>.

Published international patent application, WO 96/30372 A1, is a Japanese language document with no apparent English equivalent readily available. According to the English abstract included in the published application, the reference appears to discuss diazabicyclo[3.3.1]nonane derivatives; intermediates thereof; and a nicotinic cholinergic agent containing the diazabicyclo[3.3.1]nonane derivatives. The compounds were alleged to have a nicotinic cholinergic effect and a dopamine-releasing effect, and alleged to be usable as a remedy

for dementia such as Alzheimer's disease, a drug for relieving memory disorders, a remedy for central nerve degeneration diseases, and a drug for relieving cerebral function disorders.

Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer.

This statement should not be construed as a representation that a search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of all available information, and to form independent opinions as to its significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

Date: May 25, 2004

Carl B. Massey, Jr.

Attorney for Applicants Registration No. 44,224

Docket:

T103 1421.1

Womble Carlyle Sandridge & Rice, PLLC Post Office Box 7037 Atlanta, Georgia 30357-0037 Telephone (336) 721-3681 Facsimile(336) 726-8074



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

SERIAL NO. ATTY DKT NO. 09/864,905 T103 1421.1 APPLICANT

SUPPLEMENTAL INFORMATION DISC

CLOSURE	Miller, et al. FILING DATE 05/24/2001	GROUP 1624
<u> </u>		<u></u>

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				05/24/2001	1624	1624				
	<u>~_</u>			ATENT DOCUMENTS	S				G D 1 ED	
XAMINER		DOCUMENT	DATE NAME			CL.	SUBCL		FILING DATE IF APPROP.	
INITIAL	P1	NO. 6,635,645 21 Oct 2003 Lo		Lochead, et al.	51	4	252.01			
				N PATENT DOCUME COUNTE	NTS	CL.	SUBCL	TRANS	LATION	
		DOCUMENT N	IO. DAT	E				YES	NO	
	F1	WO 96/30372 A	.1 03 Oct 1	996						
	-							 		
	1				Dti-ont n		tc)			
		OTHER DO	CUMENTS (Incl. Author, Title, Dat	e, Pertinent p	ages, co				
										
	1_									
EVALUE I				DA	TE CONSIDE	RED				
EXAMINE	K 			itation is in conform			1 1:	through of	tation if 1	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.